CNJ-016 1 [iU]/mL
Vaccinia Immune Globulin Intravenous (Human) · INJECTION · Emergent BioSolutions Canada Inc.
Cnj-016 is an intravenous injection containing human immunoglobulin G used to treat complications from vaccinia virus infection, such as those that may occur after smallpox vaccination. It works by providing antibodies to help the body fight off vaccinia virus-related complications.
Key Facts
- Brand Name
- CNJ-016
- Generic Name
- Vaccinia Immune Globulin Intravenous (Human)
- NDC Code (Product)
60492-0173- Manufacturer
- Emergent BioSolutions Canada Inc.
- Strength
- 1 [iU]/mL
- Dosage Form
- INJECTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA125109
- Drug Class
- Human Immunoglobulin G [EPC]
- Marketing Start
- 05/02/2005
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is CNJ-016 used for?
Cnj-016 is an intravenous injection containing human immunoglobulin G used to treat complications from vaccinia virus infection, such as those that may occur after smallpox vaccination. It works by providing antibodies to help the body fight off vaccinia virus-related complications.
Is CNJ-016 a controlled substance?
CNJ-016 is not classified as a controlled substance by the DEA.
What is the generic name for CNJ-016?
The generic name for CNJ-016 is Vaccinia Immune Globulin Intravenous (Human). There are no other listed brand versions of Vaccinia Immune Globulin Intravenous (Human).
What is the NDC code for CNJ-016 1 [iU]/mL?
The NDC (National Drug Code) for CNJ-016 1 [iU]/mL is 60492-0173, listed by Emergent BioSolutions Canada Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)